Tuesday, October 22, 2024

Cardiol Therapeutics to Advance CardiolRx™ into a Late-stage Trial in Patients with Recurrent Pericarditis

CardiolRx to be tested in a new trial targeting IL-1 blocker withdrawal in patients.
This email was sent to edwardlorilla1986.paxforex@blogger.com. Don't want to receive these emails anymore? Unsubscribe
Pharma Stocks Today, United States Post Office. P.O. Box 184 500 Venetia Rd. Pennsylvania 15367-9998

No comments:

Post a Comment

Buy and Hold This Dividend Stock Forever…

Buy and Hold This Dividend Stock Forever... and Leave It for Your Grandchildren Escape the disappoin...